Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

被引：77

作者：

Wang, Michael ^{[1
]}

Rule, Simon ^{[2
]}

Zinzani, Pier Luigi ^{[3
]}

Goy, Andre ^{[4
]}

Casasnovas, Olivier ^{[5
]}

Smith, Stephen D. ^{[6
]}

Damaj, Gandhi ^{[7
]}

Doorduijn, Jeanette K. ^{[8
]}

Lamy, Thierry ^{[9
]}

Morschhauser, Franck ^{[10
]}

Panizo, Carlos ^{[11
]}

Shah, Bijal ^{[12
]}

Davies, Andrew ^{[13
]}

Eek, Richard ^{[14
]}

Dupuis, Jehan ^{[15
]}

Jacobsen, Eric ^{[16
]}

Kater, Arnon P. ^{[17
]}

Le Gouill, Steven ^{[18
]}

Oberic, Lucie ^{[19
]}

Robak, Tadeusz ^{[20
]}

Jain, Preetesh ^{[1
]}

Frigault, Melanie M. ^{[21
]}

Izumi, Raquel ^{[21
]}

Dorothy Nguyen ^{[21
]}

Patel, Priti ^{[21
]}

Yin, Ming ^{[21
]}

Dlugosz-Danecka, Monika ^{[22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Plymouth Univ, Sch Med, Plymouth, Devon, England

[3] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[4] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Hop Enfants, CHU Dijon, Dijon, France

[6] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[7] Inst Hematol Basse Normandie, Caen, France

[8] Erasmus MC, HOVON Lunenburg Lymphoma Phase Consortium 1 2, Rotterdam, Netherlands

[9] CHU Rennes, Rennes, France

[10] Univ Lille, CHU Lille, GRITA Grp Rech Formes Injectables & Technol Assoc, EA 7365, F-59000 Lille, France

[11] Clin Univ Navarra, Pamplona, Spain

[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[13] Univ Southampton, Canc Res UK Ctr, Fac Med, Southampton, Hants, England

[14] Border Med Oncol, Albury, Vic, Australia

[15] Hop Henri Mondor, AP HP, Unite Hemopathies Lymphoides, Creteil, France

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[17] Univ Amsterdam, Canc Ctr Amsterdam, Amsterdam Univ Med Ctr, HOVON Lunenburg Lymphoma Phase Consortium 1 2, Amsterdam, Netherlands

[18] Hop Hotel Dieu, CHU Nantes, Nantes, France

[19] Inst Univ Canc Oncopole Toulouse, Toulouse, France

[20] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

[21] Acerta Pharma, San Francisco, CA USA

[22] Jagiellonian Univ, Dept Haematol, Krakow, Poland

来源：

LEUKEMIA | 2019年 / 33卷 / 11期

关键词：

IBRUTINIB;

D O I：

10.1038/s41375-019-0575-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2762 / 2766

页数：5

共 50 条

[1] Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Michael Wang
Simon Rule
Pier Luigi Zinzani
Andre Goy
Olivier Casasnovas
Stephen D. Smith
Gandhi Damaj
Jeanette K. Doorduijn
Thierry Lamy
Franck Morschhauser
Carlos Panizo
Bijal Shah
Andrew Davies
Richard Eek
Jehan Dupuis
Eric Jacobsen
Arnon P. Kater
Steven Le Gouill
Lucie Oberic
Tadeusz Robak
Preetesh Jain
Melanie M. Frigault
Raquel Izumi
Dorothy Nguyen
Priti Patel
Ming Yin
Monika Długosz-Danecka
Leukemia, 2019, 33 : 2762 - 2766
[2] Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
Witzig, Thomas E.
Vose, Julie
Zinzani, Pier Luigi
Habermann, Thomas Matthew
Tuscano, Joseph M.
Sinha, Rajni
Williams, Michael E.
Drach, Johannes W.
Ramchandren, Rod
Besisik, Sevgi Kalayoglu
Zhang, Lei
Cicero, Sherri
Fu, Tommy
Goy, Andre
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Balasubramanian, Sriram
Schaffer, Michael
Deraedt, William
Davis, Cuc
Stepanchick, Emily
Aquino, Regina
Yuan, Zhilong
Kranenburg, Britte
Avivi, Irit
Dreyling, Martin
Rule, Simon
Wang, Michael
Zhuang, Sen Hong
Rizo, Aleksandra
Lenz, Georg
BLOOD, 2014, 124 (21)
[4] SINGLE-AGENT LENALIDOMIDE FOR THE TREATMENT OF RELAPSED OR REFRACTORY AGGRESSIVE LYMPHOMA PATIENTS
Puccini, B.
Chitarrelli, I.
Antognoli, G.
Fabbri, A.
Rigacci, L.
Lenoci, M. P.
Lauria, F.
Bosi, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 288 - 288
[5] Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
Alrawashdh, Neda
Alkhatib, Nimer
McBride, Ali
Persky, Daniel
Abraham, Ivo
BLOOD, 2018, 132
[6] Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL)
O'Connor, O.
Hamlin, P.
Moskowitz, C.
Straus, D.
Noy, A.
Wright, J.
Neylon, E.
MacGregor-Cortelli, B.
Portlock, C.
Zelenetz, A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[7] Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
Witzig, Thomas E.
Zinzani, Pier Luigi
Habermann, Thomas M.
Tuscano, Joseph M.
Drach, Johannes
Ramchandren, Radhakrishnan
Besisik, Sevgi Kalayoglu
Takeshita, Kenichi
Bravo, Marie-Laure Casadebaig
Zhang, Lei
Fu, Tommy
Goy, Andre
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (10) : E575 - E583
[8] Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib
Jain, Preetesh
Kanagal-Shamanna, Rashmi
Zhang, Shaojun
OK, Chi Young
Navsaria, Lucy
Nastoupil, Loretta
Lee, Hun Ju
Tang, Guilin
Yin, C. Cameron
Badillo, Maria
Nair, Ranjit
Li, Shaoying
Patel, Keyur M.
Flowers, Christopher
Vega, Francisco
Wang, Linghua
Wang, Michael L.
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : E137 - E140
[9] Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
Alrawashdh, Neda
McBride, Ali
Slack, Marion
Abraham, Ivo
BLOOD, 2020, 136
[10] Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma
Song, Yuqin
Li, Jianyong
Zhou, Keshu
Ke, Xiaoyan
Cai, Zhen
Zhang, Huilai
Yao, Tingting
Xia, Zhen
Wang, Yiqiu
Lai, Peiqiong
Liu, Xiaofeng
Zhu, Jun
LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 647 - 652

← 1 2 3 4 5 →